Dr. Smith Discusses CAR T Cells in Multiple Myeloma – OncLive
OncLive |
Dr. Smith Discusses CAR T Cells in Multiple Myeloma
OncLive The target of CAR T-cell therapy in multiple myeloma seems to be anti–B-cell maturation antigen (BCMA), says Smith. The investigational BCMA CAR T-cell therapy bb2121 had an objective response rate of 78% in patients with relapsed/refractory disease, … |
